SKYZoster vs. Shingrix: Key Differences
When looking into shingles vaccination for adults aged 50 and older or for your parents, the key differences between SKYZoster and Shingrix come down to how each vaccine is made—live attenuated versus recombinant—the number of doses required, and the immune status needed to receive it. SKYZoster is a live attenuated vaccine made by weakening a live virus, and it requires only one dose. Shingrix, by contrast, is a recombinant vaccine that combines a specific protein with an immune adjuvant rather than using a live virus, so it is given in two separate doses.
In the past, many people chose Zostavax, a live vaccine, for shingles vaccination. That changed in 2024, when its manufacturer MSD voluntarily decided to discontinue worldwide manufacturing and supply of Zostavax. As a result, the shingles vaccines now available in Korea are mainly SK bioscience's SKYZoster and GSK's Shingrix.
SKYZoster is a live attenuated vaccine given as a single dose to adults aged 50 and older. A live attenuated vaccine uses a weakened form of the virus that causes chickenpox and shingles, so that in someone with normal immune function it stimulates the immune system without causing disease.
Shingrix, on the other hand, is a recombinant vaccine that contains no live virus at all. Instead of using the whole virus, it isolates only the gE antigen—a protein found on the virus's surface—and combines it with AS01B, an adjuvant that strongly boosts the body's immune response. It is approved not only for adults aged 50 and older but also for adults aged 18 and older whose immune function is weakened by disease or treatment, putting them at higher risk of shingles. Per the approved labeling, it is given in two doses, two months apart. If the schedule needs adjusting, the second dose can be given anywhere from 2 to 6 months after the first; in immunocompromised individuals where a shorter interval is considered beneficial, it can be given 1 to 2 months after the first (Korea Ministry of Food and Drug Safety, Shingrix prescribing information).
Shingrix only produces its intended immune response once both doses have been completed, so it's better to plan ahead from the first injection, factoring in when the second dose can be finished a few months later. If surgery or chemotherapy is scheduled, coordinate the vaccination timing with the treating physician in advance so it doesn't overlap with the treatment plan.
If You're Taking Immunosuppressants
For patients whose immune function is lowered by an underlying condition or its treatment, the choice between the two vaccines is limited. Live vaccines, which contain a weakened live virus, are in principle contraindicated for immunocompromised patients (Lim Delwyn Zhi Jie et al., 2024).
When the immune system works normally, it easily overcomes the weakened virus and builds immunity in the process. But in people undergoing chemotherapy for cancer, or taking immunosuppressants after a hematopoietic stem cell transplant or organ transplant, that defense capacity is greatly reduced. The prescribing information for SKYZoster lists immunodeficient patients and those on immunosuppressive therapy — including high-dose corticosteroids — as contraindicated. It states that if such patients receive the vaccine, disseminated disease, a condition in which the vaccine virus spreads throughout the body, may occur (Korea Ministry of Food and Drug Safety, SKYZoster prescribing information). Topical or inhaled corticosteroids and low-dose systemic corticosteroids are not covered by this contraindication. People receiving immunosuppressive treatment for rheumatoid arthritis or inflammatory bowel disease should first check their medications and dosages with their physician.
For people with weakened immunity, a recombinant vaccine containing no live virus is used instead. A recombinant vaccine contains only viral protein fragments and an adjuvant, so there is no possibility of the virus multiplying or causing infection in the body. This makes it available to high-risk individuals aged 18 and older whose immunity is lowered by disease or its treatment.
Some patients who feel fine day to day don't realize that a medication they take counts as immunosuppressive treatment. A drug prescribed long ago to ease joint pain or chronic inflammation may contain an ingredient that modulates or suppresses the immune system. Before deciding on vaccination, then, patients should first go through their underlying conditions and the names of the medications they take every day, one by one.
How Was the Preventive Effect Reported?
The purpose of the shingles vaccine is to prevent shingles itself, which causes a blistering rash, and to prevent postherpetic neuralgia, which can follow after the illness. Even after all the skin rash from shingles has cleared, neuropathic pain can persist for months or, in longer cases, years along the nerves damaged by the virus. Once this neuralgia sets in, patients may take medications such as antidepressants or anticonvulsants and undergo nerve blocks to reduce the pain, but treatment is not easy (Adriaansen Elisabeth J M et al., 2024), and once nerve damage has become established, it is difficult to reverse.
The preventive effect of Shingrix, a recombinant vaccine, was reported with specific figures in large-scale clinical trials. In a trial of adults aged 50 and older followed for an average of 3.2 years, efficacy against shingles onset was 97.2% (Lal Himal et al., 2015). In a trial of adults aged 70 and older, preventive efficacy was reported at 89.8% (Cunningham Anthony L et al., 2016). For preventing the complication of postherpetic neuralgia, the rate was 91.2% in those aged 50 and older (Lim Delwyn Zhi Jie et al., 2024) and 88.8% in those aged 70 and older (Cunningham Anthony L et al., 2016).
In a manufacturer-supported study that continued following participants from the two preceding trials and used the placebo-group data from those trials as a comparison, overall efficacy from one month after the second dose was 87.7% (95% CI 84.9–90.1%), efficacy over the six years starting around 5 years after vaccination was 79.8%, and efficacy in year 11 alone was 82.0% (95% CI 63.0–92.2%) (Strezova Ana et al., 2025).
For SKYZoster, a clinical trial in Korea demonstrated that the antibody-based immune response it produces in the body is not inferior to that of Zostavax, the existing live vaccine (Choi Won Suk et al., 2019). However, this trial measured the magnitude of the immune response through blood tests, and it was not a trial that directly measured how much it reduces the incidence of shingles.
Common Reactions After Vaccination
Shingrix contains an adjuvant that strongly boosts the immune response, so a considerable proportion of recipients experience discomfort for a short period after vaccination. Common symptoms include local reactions such as injection-site pain, redness, and swelling, and reported systemic reactions include myalgia, fatigue, headache, chills, fever, and gastrointestinal symptoms (Lim Delwyn Zhi Jie et al., 2024). In clinical trial records for adults aged 70 and older, 79.0% of the vaccine group experienced an injection-site or systemic reaction within 7 days of vaccination, compared with 29.5% in the placebo group. However, the rate of serious adverse events involving hospitalization or considered life-threatening was similar between the vaccine group and the placebo group (Cunningham Anthony L et al., 2016).
Common reactions to the live vaccine include redness, pain, and swelling at the injection site, along with fever, headache, and body aches (Lim Delwyn Zhi Jie et al., 2024). This is not data on SKYZoster, but among 23,092 adverse event reports for Zostavax in the United States, the vaccine virus was confirmed by testing in 6 reports, which involved herpes zoster, varicella-like symptoms, and injection-site reactions with blistering (Miller Elaine R et al., 2018). In a Korean clinical trial of SKYZoster, 50.73% of vaccinated participants experienced an adverse event within 6 weeks of vaccination, which was not statistically different from the 48.91% seen in the Zostavax control group, and most of the reported reactions were mild (Choi Won Suk et al., 2019).
When to Avoid or Postpone Vaccination
Regardless of which vaccine you choose, some criteria for avoiding vaccination apply to both. People with hypersensitivity to any vaccine component should not receive either vaccine (Korea Ministry of Food and Drug Safety, SKYZoster and Shingrix prescribing information). People who experienced a severe allergic reaction—such as difficulty breathing or generalized urticaria—after a previous dose should likewise not receive the vaccine (Lim Delwyn Zhi Jie et al., 2024).
SKYZoster is contraindicated in people who have had anaphylaxis to neomycin, in people with untreated active tuberculosis, and in pregnant women or women who may become pregnant. People who receive SKYZoster should avoid pregnancy for three months after vaccination. People who are breastfeeding should also not receive SKYZoster. People with an acute illness, such as a fever above 38.0°C, should consider postponing vaccination (Korea Ministry of Food and Drug Safety, SKYZoster prescribing information).
For Shingrix, vaccination during pregnancy is not listed as a contraindication, but pregnant women are advised to avoid it as a precaution. People with an acute severe febrile illness or an acute infection should postpone Shingrix vaccination. People with only a mild infection, such as a common cold, do not need to postpone vaccination. In people with thrombocytopenia or another coagulation disorder, the intramuscular injection may cause bleeding, so the vaccine should be given with caution (Korea Ministry of Food and Drug Safety, Shingrix prescribing information).
If You've Already Had Shingles or Received Zostavax
Shingles occurs when the varicella-zoster virus, which lies dormant in nerve ganglia, reactivates as immunity declines. Having shingles once does not produce complete, lifelong immunity, so the condition can recur over time (Patil Anant et al., 2022). For this reason, even someone who has had shingles before may consider vaccination to prevent a recurrence. However, if you currently have active shingles, vaccination is not given right away — it takes place only after all the skin rash has cleared (Lim Delwyn Zhi Jie et al., 2024).
People who previously received the live vaccine Zostavax can also see the protection it provided wane over time. In a manufacturer-supported study, adults aged 65 and older who had received the live vaccine more than five years earlier showed immune responses and safety similar to those of first-time vaccine recipients when they received the recombinant vaccine (Dagnew Alemnew F et al., 2021). This study did not evaluate intervals shorter than five years, and the U.S. Centers for Disease Control and Prevention recommends waiting at least 8 weeks after a Zostavax shot before receiving the recombinant vaccine (Dagnew Alemnew F et al., 2021). Even those who have had Zostavax can still receive Shingrix, and the appropriate interval for each person should be decided in consultation with a healthcare provider.
What to Consider When Choosing
First, consider age together with immune status. If you are 50 or older with no significant immune disease, you fall within the eligible group for both vaccines. However, if you are between 18 and 49 years old and have a higher risk of shingles due to illness or treatment that has weakened your immune system, or if you are 50 or older but currently undergoing cancer treatment or taking immunosuppressants, the live vaccine is contraindicated in principle, so the recombinant vaccine should be considered first.
Next, consider the cost. Overall, Shingrix requires two doses in total, and the cost per dose is also higher than that of the live vaccine. For this reason, when estimating cost, don't look only at the price of a single injection — factor in the total number of doses needed to complete the vaccination series.
This content is provided for medical information purposes, and individual circumstances may vary. Please consult a specialist for accurate diagnosis and treatment.
Related medical definitions can be found at Linkare Knowledge: Shingles Vaccination.
References
- Lim Delwyn Zhi Jie, Tey Hong Liang, Salada Brenda Mae Alferez (2024). Herpes Zoster and Post-Herpetic Neuralgia-Diagnosis, Treatment, and Vaccination Strategies.. Pathogens. PMID: 39057822
- Patil Anant, Goldust Mohamad, Wollina Uwe (2022). Herpes zoster: A Review of Clinical Manifestations and Management.. Viruses. PMID: 35215786
- Adriaansen Elisabeth J M, Jacobs Julien G, Vernooij Lisette M (2024). 8. Herpes zoster and post herpetic neuralgia.. Pain Pract. PMID: 39364882
- Lal Himal, Cunningham Anthony L, Godeaux Olivier (2015). Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.. N Engl J Med. PMID: 25916341
- Cunningham Anthony L, Lal Himal, Kovac Martina (2016). Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.. N Engl J Med. PMID: 27626517
- Strezova Ana, Díez Domingo Javier, Cunningham Anthony L (2025). Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications. EClinicalMedicine. PMID: 40630610
- Choi Won Suk, Choi Jung Hyun, Jung Dong Sik (2019). Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older. Vaccine. PMID: 31122860
- Miller Elaine R, Lewis Paige, Shimabukuro Tom T (2018). Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.. Hum Vaccin Immunother. PMID: 29580194
- Dagnew Alemnew F, Klein Nicola P, Hervé Caroline (2021). The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.. J Infect Dis. PMID: 32103273
- Ministry of Food and Drug Safety (Korea), nedrug. SKYZoster prescribing information. https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=201707343 (accessed 2026-11-06)
- Ministry of Food and Drug Safety (Korea), nedrug. Shingrix prescribing information. https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=202106382 (accessed 2026-11-06)
Frequently Asked Questions
Q. What's the difference between SKYZoster and Shingrix?
SKYZoster and Shingrix differ in how the vaccine is made, how many doses it requires, and whether it can be given to immunocompromised patients. SKYZoster is a live attenuated vaccine given as a single dose, while Shingrix is a recombinant vaccine made from a viral protein fragment combined with an adjuvant, given in two doses. Recombinant vaccines can be used in immunocompromised patients, but live vaccines are contraindicated in principle.
Q. I'm taking an immunosuppressant. Can I still get the shingles vaccine?
Live vaccines, which contain a live virus, raise safety concerns in people with weakened immunity, so they generally aren't used in this group. Shingrix, however, is a recombinant vaccine, so vaccination may still be considered even during cancer treatment or while taking immunosuppressants. That said, the right timing for vaccination can vary depending on the treatment schedule and immune status, so it's important to check with your doctor first.
Q. Do I still need Shingrix if I've already had shingles?
Having had shingles once does not completely eliminate the risk of recurrence. The immunity that forms after a natural infection can weaken over time, and recurrence is possible, especially with older age or a weakened immune system. So even if you've already had shingles, you may consider vaccination once the rash has completely cleared.
Q. Why does Shingrix require two doses?
Shingrix uses only a portion of the virus's protein as its antigen rather than the whole virus, so two doses are needed to induce a sufficient immune response. The standard schedule is a first dose to trigger the immune response, followed by a second dose two months later to reinforce it. If scheduling adjustments are needed, the second dose may be given anywhere between 2 and 6 months after the first.
Q. At what age should you get the shingles vaccine?
Under Korean approval standards, both SKYZoster and Shingrix are indicated for adults age 50 and older. Shingrix also covers adults age 18 and older whose immunity is lowered by illness or treatment, putting them at higher risk for shingles. Because the risk of shingles and postherpetic neuralgia increases with age, those in their 50s should weigh their immune status and overall health together when deciding on timing.
